Literature DB >> 8563062

Volumetric bone mineral density--a potential role in paediatrics.

C T Cowell1, P W Lu, S A Lloyd-Jones, J N Briody, J R Allen, I R Humphries, E Reed, J Knight, R Howman-Giles, K Gaskin.   

Abstract

The use of areal bone mineral density (aBMD) in paediatric populations has aroused some concern, as it fails to take the age-related increase in bone thickness into account. We have developed a measure of true bone density, volumetric bone mineral density (vBMD), which is independent of age and height. In order to examine the relationship between growth parameters, aBMD and vBMD, we studied patients with phenylketonuria (PKU, n = 40), chronic renal failure (CRF, n = 27) and chronic asthma (n = 19). aBMD of the femoral neck and the mid-femoral shaft was measured using dual energy X-ray absorptiometry (DXA), vBMD was calculated on the basis of values of bone mineral content and bone dimension provided by DXA, with the assumption that both sites are cylinders. aBMD and vBMD were then compared with the normal reference, expressed as a standard deviation score (SDS). aBMD and vBMD were normal in the femoral neck region of the PKU group, but aBMD, either standardized for age or for height, was low in the femoral shaft region (p < 0.01). In the CRF group, profound growth retardation was seen (mean height SDS, -3.2) and aBMD and vBMD were both low in the femoral shaft region but not in the femoral neck. In the asthma group, aBMD for age was low at both sites, but vBMD did not differ from that seen in normal individuals. We conclude that the true vBMD provides a different interpretation of bone density compared with aBMD and requires further evaluation in paediatrics because of its age and height independence.

Entities:  

Mesh:

Year:  1995        PMID: 8563062     DOI: 10.1111/j.1651-2227.1995.tb13852.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  9 in total

1.  Normal bone mineral density in cystic fibrosis.

Authors:  D S Hardin; R Arumugam; D K Seilheimer; A LeBlanc; K J Ellis
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria.

Authors:  Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz
Journal:  J Bone Miner Metab       Date:  2010-08-13       Impact factor: 2.626

3.  Pubertal bone growth in the femoral neck is predominantly characterized by increased bone size and not by increased bone density--a 4-year longitudinal study.

Authors:  M Sundberg; P Gärdsell; O Johnell; E Ornstein; M K Karlsson; I Sernbo
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

Review 4.  Bone density in cerebral palsy.

Authors:  Christine Murray Houlihan; Richard D Stevenson
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

Review 5.  Osteoporosis in paediatric patients with spina bifida.

Authors:  Humberto Marreiros; Humberto Filipe Marreiros; Clara Loff; Eulalia Calado
Journal:  J Spinal Cord Med       Date:  2012-01       Impact factor: 1.985

6.  Bone mineral density in patients with classic galactosaemia.

Authors:  M E Rubio-Gozalbo; S Hamming; M J P G van Kroonenburgh; J A Bakker; C Vermeer; P Ph Forget
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

Review 7.  Methods for measurement of pediatric bone.

Authors:  Teresa L Binkley; Ryan Berry; Bonny L Specker
Journal:  Rev Endocr Metab Disord       Date:  2008-02-05       Impact factor: 6.514

8.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

9.  A one-year exercise intervention program in pre-pubertal girls does not influence hip structure.

Authors:  Gayani Alwis; Christian Linden; Susanna Stenevi-Lundgren; Henrik G Ahlborg; Jack Besjakov; Per Gardsell; Magnus K Karlsson
Journal:  BMC Musculoskelet Disord       Date:  2008-01-24       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.